Patterns and Prevalence of Germline BRCA1 and BRCA2 Mutations among High-Risk Breast Cancer Patients in Jordan: A Study of 500 Patients

Abstract EN

Purpose.

Knowledge of BRCA1 and BRCA2 mutations has a significant clinical impact on the management and prevention of breast cancer.

In this study, we evaluate the pattern and prevalence of germline mutations in BRCA1 and BRCA2 among high-risk Jordanian breast cancer patients selected as per international guidelines.

Methods.

BRCA1 and BRCA2 testing were performed at a reference genetic lab.

Mutations were classified as pathogenic/likely pathogenic and variant of uncertain significance (VUS).

Results.

A total of 517 patients, median age: 39 (range: 19–78) years, were enrolled.

Among the whole group, 72 (13.9%) patients had pathogenic or likely pathogenic BRCA1 (n = 24, 4.6%) or BRCA2 (n = 48, 9.3%) mutations, while 53 (10.3%) others had VUS.

Among 333 younger (≤40 years) patients, mutations were observed in 44 (13.2%).

Positive mutations were found in 40 (16.5%) patients with one or more close relatives with breast cancer and in 20 (35.1%) of the 57 patients with triple-negative disease.

Multivariate analysis showed that a triple-negative status, history of two or more close relatives with breast cancer, and history of one or more close relatives with invasive ovarian cancer were associated with significant high odds ratios (OR) of carrying a pathogenic variant, with an OR (95% CI) of 5.08 (2.66–9.67), 3.24 (1.78–5.89), and 2.97 (1.04–8.52), respectively.

Conclusions.

BRCA1 and BRCA2 mutations are not uncommon among Jordanian patients.

Young age has the weakest association with positive mutations, while patients with triple-negative disease, especially those with an additional positive family history, have the highest mutation rate.